N/A (Healthy adults)
Conditions
Interventions
Oral intake of test food (1 pill in once a day, 12 weeks)
Sponsors
Santen Pharmaceutical Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: [1]Males and Females aged 20 years over [2] Individuals whose written informed consent has been obtained [3]Individuals who can have an examination in a designated day [4]Individuals without ocular disease except ametropia [5]Individuals whose ocular blood flow can stably measured
Exclusion criteria
Exclusion criteria: [1] Individuals with serious disease [2] Individuals with cigarettes smoker [3]Individuals with cardiac failure, renal failure, hepatitis B or C, Hyperlipidemia, hypotension, hypertension, diabetes or a history of the said diseases [4]Individuals who continuously used a antioxidative supplement (ex. bulk of pine extracts, bilberry, blackcurrant, rutein, astaxanthin, vitamin E) or have plan to use said supplements during the study period [5] Individuals who used a drug having influence to ocular blood flow (ex. antihypertensive agents, circulation improving drugs) in the past 4 weeks. [6] Individuals who is pregnant, lactating, or may possibly be pregnant. [7] Individuals who entry into another clinical trial, or has a history of the entry into other clinical trials within 3 months [8] Individuals with allergy to test food or who may possibly be allergy to test food, or with severe allegy to other foods or drugs. [9] Individuals who are inappropriate case judged by investigator or subinvestigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Value and rate changes of optic nerve blood flow from pre-dosing at 4, 8 and 12 weeks after dosing Adverse effect | — |
Countries
Japan
Contacts
Public ContactYasutaka Takagi
Santen Pharmaceutical Co., Ltd. Japan Medical Affairs Group, Development Management Department, Japan Business
Outcome results
None listed